BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maasoumy B, Vermehren J. Diagnostics in hepatitis C: The end of response-guided therapy? J Hepatol 2016;65:S67-81. [PMID: 27641989 DOI: 10.1016/j.jhep.2016.07.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, Kamkamidze G, Krajden M, Loarec A, Njouom R, Nguyen KV, Shiha G, Soliman R, Solomon SS, Tsertsvadze T, Denkinger CM, Linas B. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. J Hepatol 2019;71:62-70. [PMID: 30797050 DOI: 10.1016/j.jhep.2019.02.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
2 Aretzweiler G, Leuchter S, García-Álvarez M, Simon C, Marins E, Paxinos E, Canchola J, Delgado R, Frontzek A. Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations. Expert Rev Mol Diagn 2019;19:941-9. [PMID: 31159598 DOI: 10.1080/14737159.2019.1624162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Loggi E, Vukotic R, Conti F, Gitto S, Andreone P. Gold standard assays for the monitoring of patients with chronic hepatitis C. Future Virology 2018;13:529-37. [DOI: 10.2217/fvl-2018-0032] [Reference Citation Analysis]
4 Sasaki R, Meyer K, Moriyama M, Kato N, Yokosuka O, Ray RB, Aurora R, Ray R, Kanda T. Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients. J Med Virol. 2018;. [PMID: 30192392 DOI: 10.1002/jmv.25310] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
5 Vermehren J, Bourlière M, Pol S, Marcellin P, Hyland RH, Jiang D, Brainard DM, Zeuzem S, Welzel TM. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. J Clin Virol 2017;89:51-6. [PMID: 28259054 DOI: 10.1016/j.jcv.2017.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Hutchinson JA, Weigand K, Adenugba A, Kronenberg K, Haarer J, Zeman F, Riquelme P, Hornung M, Ahrens N, Schlitt HJ, Geissler EK, Werner JM. Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers. Front Immunol 2018;9:146. [PMID: 29467758 DOI: 10.3389/fimmu.2018.00146] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Behrendt P, Bremer B, Todt D, Steinmann E, Manns MP, Cornberg M, Wedemeyer H, Maasoumy B. Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. Liver Int 2021;41:1815-23. [PMID: 33683813 DOI: 10.1111/liv.14870] [Reference Citation Analysis]
8 Sandmann L, Manns MP, Maasoumy B. Utility of viral kinetics in HCV therapy - It is not over until it is over? Liver Int 2019;39:815-7. [PMID: 31020775 DOI: 10.1111/liv.14047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Mücke MM, Maasoumy B, Dietz J, Mücke VT, Simon CO, Canchola JA, Cornberg M, Marins EG, Manns MP, Zeuzem S, Wedemeyer H, Sarrazin C, Vermehren J. Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. PLoS One 2019;14:e0224751. [PMID: 31738773 DOI: 10.1371/journal.pone.0224751] [Reference Citation Analysis]
10 Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver Int 2018;38:1906-10. [PMID: 30022590 DOI: 10.1111/liv.13932] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Emmanuel B, Wilson EM, O'Brien TR, Kottilil S, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol 2017;2:832-6. [PMID: 28802815 DOI: 10.1016/S2468-1253(17)30053-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
12 Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, Rivera-Iñiguez I, Campos-Medina L, Roman S. Adherence to a Fish-Rich Dietary Pattern Is Associated with Chronic Hepatitis C Patients Showing Low Viral Load: Implications for Nutritional Management. Nutrients 2021;13:3337. [PMID: 34684338 DOI: 10.3390/nu13103337] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cardona-Gonzalez MG, Goldman JD, Narayan L, Brainard DM, Kowdley KV. Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation. Hepatol Commun. 2018;2:1446-1450. [PMID: 30556034 DOI: 10.1002/hep4.1280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
14 Tam E, Borgia S, Yoshida EM, Cooper C, Ford J, Vachon M, Sherman M, Halsey-brandt J. Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial. CanLivJ 2019;2:91-107. [DOI: 10.3138/canlivj.2018-0024] [Reference Citation Analysis]
15 Toyoda H, Kumada T, Tada T, Yama T, Mizuno K. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J Gastroenterol Hepatol 2018;33:1264-70. [PMID: 29164675 DOI: 10.1111/jgh.14053] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Aghemo A, Piroth L, Bhagani S. What do clinicians need to watch for with direct-acting antiviral therapy? J Int AIDS Soc 2018;21 Suppl 2:e25076. [PMID: 29633552 DOI: 10.1002/jia2.25076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Applegate TL, Fajardo E, Sacks JA. Hepatitis C Virus Diagnosis and the Holy Grail. Infectious Disease Clinics of North America 2018;32:425-45. [DOI: 10.1016/j.idc.2018.02.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
18 Visco-Comandini U, Lapa D, Lionetti R, Taibi C, Loiacono L, Montalbano M, Capobianchi MR, D'Offizi G, Garbuglia AR. Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols. J Med Virol 2018;90:1264-71. [PMID: 29611880 DOI: 10.1002/jmv.25084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Aguilera A, Alados JC, Alonso R, Eiros JM, García F. Current position of viral load versus hepatitis C core antigen testing. Enferm Infecc Microbiol Clin (Engl Ed) 2020;38 Suppl 1:12-8. [PMID: 32111360 DOI: 10.1016/j.eimc.2020.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]